A Phase I Study of the Combination of Alsertib (MLN8237) and Brentuximab Vedotin in Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Alisertib (Primary) ; Brentuximab vedotin
- Indications Hodgkin's disease; Lymphoma; Solid tumours
- Focus Adverse reactions
- 30 Jun 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 30 Jun 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 30 Jun 2016 Planned initiation date changed from 1 May 2016 to 1 Sep 2016.